

# Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Andrew J. Ullmann<sup>1</sup> · Martin Schmidt-Hieber<sup>2</sup> · Hartmut Bertz<sup>3</sup> · Werner J. Heinz<sup>1</sup> · Michael Kiehl<sup>4</sup> · William Krüger<sup>5</sup> · Sabine Mousset<sup>6</sup> · Stefan Neuburger<sup>7</sup> · Silke Neumann<sup>8</sup> · Olaf Penack<sup>9</sup> · Gerda Silling<sup>10</sup> · Jörg Janne Vehreschild<sup>11</sup> · Hermann Einsele<sup>1</sup> · Georg Maschmeyer<sup>12</sup> · on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)

Received: 28 January 2016 / Accepted: 28 May 2016 / Published online: 24 June 2016  
© The Author(s) 2016. This article is published with open access at Springerlink.com

**Abstract** Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version

of the AGIHO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.

**Keywords** Infections · Viral · Fungal · Bacteria

## Introduction

Infectious complications remain a clinical challenge in the setting of allogeneic haematopoietic stem cell transplantation (allo-HCT). Particular during the early phase after allo-HCT,

✉ Andrew J. Ullmann  
andrew.ullmann@uni-wuerzburg.de

<sup>1</sup> Department of Internal Medicine II, Division of Hematology and Oncology, Division of Infectious Diseases, Universitätsklinikum, Julius Maximilian's University, Oberdürrbacher Str. 6, 97080 Würzburg, Germany

<sup>2</sup> Clinic for Hematology, Oncology und Tumor Immunology, Helios Clinic Berlin-Buch, Berlin, Germany

<sup>3</sup> Department of Hematology/Oncology, University of Freiburg Medical Center, 79106 Freiburg, Germany

<sup>4</sup> Medical Clinic I, Klinikum Frankfurt (Oder), Frankfurt (Oder), Germany

<sup>5</sup> Haematology and Oncology, Stem Cell Transplantation, Palliative Care, University Hospital Greifswald, Greifswald, Germany

<sup>6</sup> Medizinische Klinik III, Palliativmedizin und interdisziplinäre Onkologie, St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany

<sup>7</sup> Sindelfingen-Böblingen Clinical Centre, Medical Department I, Division of Hematology and Oncology, Klinikverbund Südwest, Sindelfingen, Germany

<sup>8</sup> Medical Oncology, AMO MVZ, Wolfsburg, Germany

<sup>9</sup> Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany

<sup>10</sup> Department of Internal Medicine IV, University Hospital RWTH Aachen, Aachen, Germany

<sup>11</sup> Department I of Internal Medicine, German Centre for Infection Research, Partner-site: Bonn-Cologne, University Hospital of Cologne, Cologne, Germany

<sup>12</sup> Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany

mortality rates for infections are high [1, 2]. After the first publication of recommendations from our group in 2003, [3] numerous new results of trials have been published and implemented into daily patient care. With this updated guideline, AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology) pursues a step forward to include the entire patient history up right from the beginning of the preparation of patients through the entire post allo-HCT time period.

This guideline focuses on the adult patient population only and is partitioned into four parts: (a) general precautions and prevention measures, (b) pre-transplantation (screening) phase, (c) prophylactic treatment, and (d) immunization strategies.

## Methods

Several steps were undertaken to develop the updated guideline: The first step was defining a group of specialists. They were enlisted by the AGIHO of the DGHO with a designated coordinator. The coordinator was responsible to manage the efforts of the group. The group of authors consisted of 14 certified internists, including 13 certified haematologists, and 5 certified infectious diseases specialists. Four authors are triple certified in internal medicine, infectious diseases, and haematology/oncology.

Predefined topics were elaborated by subgroups and then presented to the entire group for discussions. This included several face-to-face meetings, which were complemented by conference calls. Once the group had consensus with their results, the preliminary recommendations of the group were presented to the entire AGIHO assembly for review, discussions, modification, and final approval. All recommendations were made on the basis of available data providing evidence-

based medicine. The guideline utilized the latest version of the strength of recommendation and quality of evidence published by the ESCMID (Table 1) [4]. Specific topics related to cord blood or haplo-identical transplant recipients are not addressed by this guideline.

## General precautions

An allo-HCT requires certain assessment procedures, which are basically standardized (e.g. JACIE by the EBMT). Herein, we touch off on a few basic standardized requirements.

Patients' rooms should be equipped with air-filtered systems to keep spore counts low and, thus, preventing nosocomial fungal diseases (**BI**) [5–9]. Further, nearby construction activities should be kept to a minimum (**AII**). [10] Isolation of the stem cell recipients in a single hospital room under conditions of laminar airflow or positive pressure HEPA filtration (>12 exchanges per hour) is generally recommended.

However, randomized controlled trials focusing on HEPA filter efficacy against viral infections are lacking. Especially respiratory virus outbreaks, including seasonal pathogens such as respiratory syncytial virus (RSV) and influenza, are not prevented by HEPA filtrations [11]. Genotyping of RSV outbreaks demonstrated that more than two thirds were hospital acquired [12–15]. These results underscored the important necessity of infection control measures (i.e. barrier precautions) to prevent exposure directly at the patients' site (**AII**).

Some debate usually arises on the topic of appropriate dietary needs for patients after allo-HCT. The rule of thumb "cook it, peel it, or forget it" is easy to understand. However, there is a lack of appropriate literature on this specific topic. On the other hand, the evidence is clearer for the prevention of specific infections, e.g. listeria or other agents

**Table 1** Strength of the AGIHO (DGHO) and DAG-KBT recommendation and quality of evidence (modified according to [4])

Strength of a recommendation	
Grade A	AGIHO strongly supports a recommendation for use
Grade B	AGIHO moderately supports a recommendation for use
Grade C	AGIHO marginally supports a recommendation for use
Grade D	AGIHO supports a recommendation against use
Quality of evidence	
Level I	Evidence from at least 1 properly designed randomized, controlled trial
Level II <sup>a</sup>	Evidence from at least 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from >1 centre); from multiple time series; or from dramatic results of uncontrolled experiments
Level III	Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies

<sup>a</sup> Added index: <sub>r</sub>: meta-analysis (or systematic review of RCT); <sub>r</sub>: transferred evidence i.e., results from different patients 'cohorts' or similar immune status situation; <sub>h</sub>: comparator group: historical control; <sub>u</sub>: uncontrolled trials; <sub>a</sub>: published abstract (presented at an international symposium or meeting)

causing infectious diarrhea (**BII**) [16, 17]. Contact precautions and hand disinfection (incl. repeated teaching on this matter) can prevent nosocomial infection (**AII**) [18]. Healthcare workers (HCW) with transmissible diseases (e.g. herpes, infectious gastroenteritis, respiratory tract infections) should be restrained from direct patient care to prevent any nosocomial spread of their disease (**AIII**) [19]. Some hospital facilities have recovered microbes (e.g. *Legionella* spp.) from their drinking water. In order to prevent transmission in high-risk patients, water filters provide a protective solution though regular testing remains a necessity (**AII**) [20–22].

### Pre-transplantation (screening) phase

A comprehensive pre-transplant assessment of the allo-HCT recipient for infectious complications is a valuable tool to identify patients at increased risk for distinct infectious diseases.

Syphilis, tuberculosis, *Toxoplasma gondii*, HIV, hepatitis B and C viruses, and *Herpes viridae* usually persist lifelong in the host after primary infection and can be reactivated under certain conditions. As a consequence, all candidates for allo-HCT should undergo a test for IgG antibodies specific for viral diseases, syphilis, and toxoplasmosis. False negative results particularly could occur in the context of CLL, multiple myeloma, previous antibody treatment (e.g. rituximab), or might be false positive after IVIG application or blood product transfusion. In any case, all patients tested IgG-seronegative strictly remain on preventive measures to avoid de novo infection prior to allo-HCT and afterwards.

### Specific viruses

#### *Herpes viridae*

All candidates for allo-HCT should be tested for CMV, EBV, and VZV IgG antibodies to determine their risk for reactivation or de novo infection (**AIII**) [23–25]. Due to the high prevalence of HSV in the patient population, further antibody testing for HSV is not mandatory (**CII**) [26].

#### *Hepatitis B*

Prior to allo-HCT, besides hepatitis B virus (HBV) antibody panels, additional testing for hepatitis B surface antigen (HBsAg) should be performed [27, 28]. If tested positive for HBsAg or for anti-HBc, further HBV-DNA assessment for active replication is crucial (**AII**). If considered to be diagnosed with active hepatitis (e.g. viral replication), initiation of antiviral treatment prior to allo-HCT should be considered (**AIII**) [29].

There is a reported risk of up to 50 % for reverse seroconversion after allo-HCT if a patient is anti-HBc positive but has no detectable viral replication (resolved HBV infection) [30–32]. HBV-vaccination after allo-HCT might alleviate this risk [33].

#### *Hepatitis C*

Serologic testing for hepatitis C virus (HCV) is recommended. Serologically positive patients should receive quantitative testing for HCV-RNA viral load (**AIII**). Patients with chronic hepatitis C should receive a further diagnostic assessment, e.g., fibroscan or a liver biopsy to rule out liver fibrosis or cirrhosis. In case of liver cirrhosis or fibrosis, the conditioning regimen should try to avoid TBI, oral busulfan, or cyclophosphamide to minimize risk of hepatic sinusoidal occlusion syndrome (SOS) (**BIII**) [34–37].

#### *Hepatitis E*

Hepatitis E virus (HEV) is detected in immunocompromised patients. Limited information is available on the real incidence of HEV infection in recipients of allo-HCT [38, 39]. Mostly self-limited reactivation cases are published though chronic forms have been described as well. Serologic testing for HEV prior to allo-HCT is recommended (**BIII**). HEV should be considered as a differential diagnosis in patients after allo-HCT with elevated liver function tests [39–41].

#### *HIV*

HIV testing prior to allo-HCT is recommended. HIV-infected patients should be carefully evaluated for allo-HCT. Though HIV seropositivity per se is not a contraindication for allo-HCT [42]. If allo-HCT seems feasible, a donor screening for CCR5-Delta 32 deletion could be considered in patients with CCR5 tropism to potentially control HIV infection post-allo-HCT (**BIII**) [43, 44]. Toxicity permitting, antiretroviral therapy should be continued throughout of the post-transplantation phase (**AII**) [45]. However, recurring interruptions with low drug levels may induce viral resistance, and an interrupted treatment should not be reinstated until the patient has sufficiently recovered to allow stable tablet intake (**BIII**).

#### *Syphilis*

Serologic testing for syphilis is recommended. Frequently TPHA/TPPA or VDRL are utilized. Important are the combinations of nontreponemal (e.g. VDRL) and treponemal tests. If a nontreponemal test is positive, confirmation of infection with treponemal test (e.g. TPPA or TP-EIA) should be performed. In case of an active infection or unclear whether the

patient received an adequate treatment in the past, a treatment with penicillin should be instituted (**BIII**) [46].

### Toxoplasmosis

All candidates for allo-HCT should undergo serologic testing for toxoplasmosis. If the serology testing for toxoplasmosis IgG is positive, patients have a risk of toxoplasmosis reactivation, especially if the donor is serologically negative for toxoplasmosis [47]. Some centres propagate regular PCR testing [48]. Since the incidence in Europe is very low, regular toxoplasmosis DNA through PCR screening is not recommended (**DIII**). This is of course different in patients with clinical symptoms.

### Tuberculosis

Thorough evaluation of the medical history can identify patients at risk for latent or active tuberculosis infection (**AIII**). As most candidates have received chemotherapy or immunosuppressive treatment prior to evaluation for allo-HCT, a tuberculin skin test might be false negative and therefore cannot be recommended in this setting (**DIII**). If the medical history is suggestive of prior tuberculosis exposure, an interferon-gamma-release assay (IGRA) can be considered (**BIII**) [49]. However, a reduced sensitivity in immunocompromised patients has been demonstrated as well [50, 51].

## Prophylaxis and prevention

### Prevention of bacterial infections (screening for bacterial colonization)

In this era of easy accessibility of antibiotics, clinicians are facing the growing challenge of multi-resistant bacteria (e.g. vancomycin-resistant *Enterococci* (VRE), methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum beta-lactamase producing bacteria (ESBL), metallo- $\beta$ -lactamase-producing bacteria (MBL)). Colonization with certain multi-resistant bacteria is predictive for developing bloodstream infection, and knowledge of colonization status may therefore guide empirical antibiotic treatment, although this strategy has not been demonstrated to improve outcomes [52, 53]. We recommend screening procedures for multi-resistant bacteria, especially in institutions with a known high prevalence (**BII**) [54, 55]. Since the sensitivity of the screening methods is low, repeated testing (e.g. weekly rectal swabs) would be required [56–58]. Contact precautions between medical staff and patients remain to be necessary and separate sanitary facilities need to be guaranteed to exclude cross-patient transfer of multi-resistant bacteria [59, 60].

Antibiotic prophylaxis (e.g. ciprofloxacin) demonstrated its efficacy by reducing the incidence of Gram-negative sepsis during neutropenia without any significant change in mortality [61, 62]. All-cause mortality was reduced only in meta-analysis [63]. At institutions with a low rate of multi-resistant gram-negative bacteria, antibacterial prophylaxis remains a reasonable choice to reduce the incidence of Gram-negative sepsis during neutropenia (**AII<sub>r</sub>**) [62, 64–67]. Encapsulated bacteria such as *Streptococcus pneumoniae* or *Haemophilus influenzae* often cause severe bacterial infections in the late phase after transplantation [68–70]. In patients with chronic GVHD (graft-versus-host disease) on immunosuppressive therapy, antibiotic prophylaxis against these bacteria for disease prevention might be useful until immunizations can be applied (**BIII**). Antibiotic selection should be guided by local antibiotic resistance patterns. In patients without chronic GVHD, systemic antibiotic prophylaxis is not recommended after reconstitution of the neutrophils (**DIII**).

The value of selective gut decontamination is frequently debated and the literature points out that sepsis rates are increased and mortality outcomes were significantly worse in patients with lower intestinal diversity; therefore, no recommendation was made [71–74].

### Prophylaxis against *Pneumocystis pneumonia*

*Pneumocystis jirovecii* (previously named *Pneumocystis carinii*) pneumonia has been noted in allo-HCT recipients with an incidence of approximately 5–16 % without adequate prophylaxis and occurred at a median of 9 weeks after allo-HCT. Despite intensive treatment, mortality rates are as high as 89 % during the first 6 months and approximately 40 % after the first 6 months following allo-HCT [75, 76].

Prophylaxis against *Pneumocystis jirovecii* pneumonia is recommended for at least first 6 months after allo-HCT to prevent *Pneumocystis jirovecii* pneumonia-associated death (**AII<sub>r</sub>**). However, patients might require prophylaxis for prolonged periods of time. Recommended prophylactic regimens are similar to regimens in HIV/AIDS patients. Therefore, patients on immunosuppressive medications or active GVHD should remain on prophylaxis [77]. Once immunosuppressive medications are discontinued or no active GVHD is noted, prophylaxis may be discontinued assuming a CD4<sup>+</sup>/CD3<sup>+</sup> lymphocyte count of 200/ $\mu$ L or higher (**BII<sub>t</sub>**). Thus monitoring of CD4<sup>+</sup>/CD3<sup>+</sup> lymphocytes could be continued until the threshold is confirmed by repeated testing (**BII<sub>t</sub>**) [78]. The CD4<sup>+</sup>/CD3<sup>+</sup> lymphocyte count of 200/ $\mu$ L as a discontinuation criterion is not confirmed in the allogeneic setting, and therefore, an individual decision to discontinue can be considered (**CIII**).

The prophylactic treatment of choice is the fixed combination of trimethoprim (80 mg) and sulfamethoxazole (400 mg) once daily thrice weekly (**AII<sub>t</sub>**) [79–82]. In case of intolerance



to the trimethoprim/sulfamethoxazole therapy, aerosolized pentamidine (300 mg) every 4 weeks (**BI<sub>1</sub>**) or atovaquone (750 or 1500 mg daily) (**BI<sub>2</sub>**) is recommended [83–89]. Dapsone (100 mg) cannot be recommended (**DII<sub>1</sub>**) [90]. Protective efficacy against *Pneumocystis* appears to be less with these alternative drugs compared to trimethoprim/sulfamethoxazole [84, 86, 90–93].

### Antifungal prophylaxis in allo-HCT

Invasive fungal diseases (IFDs) are severe complications associated with prolonged hospital length of stay, costs, long-term treatment, and high mortality [94]. Approximately two thirds of the IFD develop in allo-HCT patients after leukocyte recovery [95, 96]. Furthermore, intensifying immunosuppression for treatment of transplant rejection or GvHD and CMV infection impose an imminent risk for IFD [97, 98].

The incidence of invasive aspergillosis (IA) varies between reports and may reach 23 % [94, 99]. Primary prophylaxis is highly recommended since diagnostic tools do not present with sufficient sensitivity numbers. This is mirrored in studies with a significant number of post-mortem diagnoses of fungal diseases [100–102]. In patients diagnosed with IA, mortality rates of up to 60 % have been reported despite adequate treatment [103]. Secondary prophylaxis is recommended prior to allo-HCT (**BI<sub>1</sub>**) [104].

Invasive candidiasis, predominantly manifesting as candidemia, is the second most frequent IFD in allo-HCT patients. Invasive candidiasis/candidemia typically manifests in patients with underlying conditions after being exposed to additional risk factors, e.g. intravascular devices, broad-spectrum antibiotic treatment, total parenteral nutrition, or *Candida* colonization [105–107].

The currently largest cohort of IFDs shows an 8 % share of mucormycosis in all IFDs in allo-HCT, followed by a number of other rare mould infections [94]. Approximately half of the patients diagnosed with mucormycosis are patients after allo-HCT [108]. The share of rare IFDs like those caused by the order of *Mucorales* or *Fusarium* spp. appear to be increasing [94, 109]. Newer agents like isavuconazole demonstrated favorable response rates in primary treatment against moulds; however, larger prophylaxis studies are still needed [110–112].

In Table 2, prophylactic recommendations are summarized. Our group recently published recommendations for the treatment (i.e. targeted therapy) of fungal diseases [113].

### Herpes simplex virus 1/2 prevention

*Herpes viridae* persist in the host after primary infection. Up to 80 % of adults are HSV-seropositive and especially during immunosuppression HSV may begin to replicate. Without prophylaxis allo-HCT recipients have a risk of approximately

80 % to reactivate during the early phase mainly during the first 4 weeks after allo-HCT [19, 137, 138]. Dissemination may lead to severe illness with substantial morbidity and mortality. As a consequence, patients should receive acyclovir early on for the prevention of disease to reduce mortality (**AI**) [138–141] (Table 3).

The duration of prophylaxis should last for up to 30 days after allo-HCT (**AI**) [139, 141]. However, exceptions are defined by recurrent episodes of HSV disease or risk of *Varicella zoster* disease. In these situations, duration of acyclovir prophylaxis to prevent disease is prolonged to a year or longer especially during intensified immunosuppressive therapy (**BI<sub>1</sub>**) [142].

Resistance to acyclovir is a rare event and mainly caused by reduced activity or mutations of viral thymidine kinase resulting in reduced activation of acyclovir in infected cells [143, 144]. Breakthrough infections are noted but are usually described as clinically resistant since prophylaxis failure is explainable by decreased bioavailability of acyclovir. In cases of real acyclovir-resistant HSV, foscarnet susceptibility remains, and this agent is considered as an alternative treatment option for acyclovir-resistant disease (**BI<sub>2</sub>**). However, it cannot be recommended for routine prophylaxis due to its significant toxicity (**DIII**) [145].

It is presumed that valacyclovir and famciclovir are effective for the prevention of HSV reactivation; however, there are no clinical trials in allo-HCT to better support a recommendation (**CIII**) [146, 147].

### *Varicella zoster* virus prevention

Since *Varicella zoster* virus (VZV) is highly contagious, patients with VZV disease should be isolated to prevent nosocomial spreading of viruses until all lesions are crusted (**AIII**) [148, 149]. Patients should be informed of the easy transmission of VZV. Allo-HCT recipients without adequate antiviral prophylaxis are at risk for disease, since up to two thirds develop herpes zoster, which mainly occurs 3 to 12 months after allo-HCT [150]. VZV seronegative family members, healthcare workers, other contact persons of allo-HCT recipients, or children without a history of *Varicella* or immunization, should be advised to receive a vaccination against VZV ideally at least 4 weeks prior to planned allo-HCT (**BIII**) [151].

Primary infection is rare and is associated with a high rate of mortality caused by frequent dissemination (e.g. encephalitis, pneumonia, viscera, or hepatitis) [150, 152, 153]. Therefore, exposure of seronegative recipients to chickenpox, zoster or vaccinated persons who experience a rash after vaccination should be avoided to prevent primary disease or VZV-associated death (**BIII**). If exposure to persons with chickenpox or zoster

**Table 2** Antifungal prophylaxis

Intention	Intervention	SoR	QoE	Comments	Ref
Prevent mould infection in patients without GvHD, day 1–100	Voriconazole 200 mg bid oral or iv <sup>b</sup>	C	I	No difference seen in the trial in comparison to fluconazole	[114]
	Posaconazole (suspension) 200 mg tid <sup>b</sup>	B	II <sub>t</sub>	Improved overall survival in AML/MDS induction during neutropenia, new formulations (tablet and iv, 300 mg qid) provide a better bioavailability	[115–117]
	Micafungin 50 mg/day	C	I	Only during neutropenia, morbidity advantage	[118]
	Itraconazole suspension 2.5–7.5 mg/kg or capsules	C	I	Administered up to 180 days if GVHD was diagnosed; higher toxicity in comparison to fluconazole, TDM: cutoff at 500 mg/mL (AII)	[119–121]
Prevent invasive <i>Candida</i> disease in patients without GvHD, day 1–100	Fluconazole 400 mg/day	A	I	Improved survival, note rising incidence of resistant <i>Candida</i> species since studies were published	[122–124]
	Voriconazole 200 mg bid oral or iv <sup>b</sup>	B	II <sub>t</sub>	Also active against moulds, but no difference seen in the trial between voriconazole and fluconazole	[114]
	Posaconazole (suspension) 200 mg tid <sup>b</sup>	B	II <sub>t</sub>	Also effective against moulds, new formulations (tablet and iv, 300 mg qd) provide a better bioavailability	[115, 117]
	Micafungin 50 mg/day	B	II <sub>t</sub>	Also effective against moulds, only during neutropenia, morbidity advantage	[118]
	Itraconazole suspension 2.5–7.5 mg/kg or capsules <sup>b</sup>	C	I	See above	[119–121]
Prevent invasive Aspergillosis during GvHD	Posaconazole (suspension) 200 mg tid <sup>b</sup>	A	I	improved survival (lower attributable mortality), new formulations (tablet and iv, 300 mg qd) provide a better bioavailability	[117, 125]
Prevent fungal disease relapse (previous IFD)	Voriconazole <sup>b</sup>	B	II	considered as secondary antifungal prophylaxis, dosages as above	[126]
	Caspofungin, posaconazole	B	III		[127, 128]
Prevent fungal diseases <sup>a</sup>	Amphotericin B deoxycholate	D	II	Inacceptable toxicity	[129–131]

<sup>a</sup> other formulations and various dosages and application regimens of Amphotericin B have been evaluated with different results in small studies, all would need further evaluation to provide any kind of recommendation [132–134]

<sup>b</sup> Consider TDM, serum levels of efficacy in prophylaxis are still debated, e.g. posaconazole [135]

occurs, passive immunization with anti-VZV hyperimmunoglobulin (Ig) within 96 h after exposure is considered optional (**CIII**), as efficacy has not been proven [154, 155]. Antiviral therapy with valacyclovir 1 g po tid or acyclovir 800 mg qid should be administered (**BIII**) immediately to prevent disease in seronegative recipients.

Main antiviral prophylaxis recommendations are summarized in Table 3. Various authors [156–159] noted that even prolonged administration for approximately 1 year or longer is considered safe and there was no higher incidence of disease after drug discontinuation. Longer than 12-month periods appears to be beneficial as long as patients remain on intensified immunosuppressive therapy (**BIII**).

If resistance to acyclovir is suspected, foscarnet or cidofovir are alternative agents (**BIII**) [160]. Brivudine is contraindicated in patients receiving 5-fluoropyrimidine derivatives and was not assessed in immunocompromised patients (**DIII**). (<http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RHB/2012/rhb-zostex.html>, last accessed May 1, 2016)

### CMV disease prevention

All CMV-seronegative recipients ideally should receive a CMV-seronegative donor graft to prevent infection and reduce mortality (**AII**) [25, 161, 162]. To further prevent disease, CMV-seronegative recipients transplanted from a negative donor should only receive blood products from CMV-seronegative donors upon availability. Blood banks without a sufficient pool of CMV-negative donors should deliver only leukocyte-depleted red blood cells and thrombocytes (**AII**) [163]. However, data from various studies suggest if blood products are leukocytes reduced, testing for CMV-negative blood products is not needed for HSCT recipients (**AII**) [163–165]. Noteworthy, irradiation to prevent transfusion-associated GvHD does not inactivate CMV [164, 166–170].

Special risk factors for CMV infection or disease are T cell-depleted graft, HLA-mismatched transplantation, steroid treatment, and acute or chronic GvHD [171–173]. All patients at risk for CMV disease should be screened regularly for pp65 antigenemia or by nucleic acid detection methods after allo-HCT (**AII**) [174].

**Table 3** Antiviral prophylaxis

Intention	Intervention	SoR	QoE	Comments	Ref
<b>HSV</b>					
Prevent HSV disease	Acyclovir 400 mg tid/day	A	II	Up to 30 days post allo-HCT (various dosages)	[139, 141, 233]
	Valacyclovir 500 mg bid /day	A	II		[234]
	Acyclovir any dosage	D	III	Beyond 30 days if patient is also VZV seronegative	
<b>VZV</b>					
VZV disease prevention in VZV seropositive recipients	Acyclovir 800 mg bid	A	I	Up to 1 year after allo-HCT	[156]
	Acyclovir 400 mg/day	B	II		[158, 159, 235]
	Valacyclovir 500 mg bid	B	II		[236, 237]
	Acyclovir 200 mg/day	B	II		More than 365 days if continued on immunosuppressive therapy [233, 238]
Prevent VZV in seronegative patients	No prophylaxis	C	III		
Prevent VZV in seronegative patients if exposed	Passive immunization	C	II <sub>t</sub>	Within 96 h post exposure, optional	[155]
	Acyclovir or other VZV-active antiviral	C	III		
Prevent VZV disease after exposure	Vaccination	–	–	No data to provide recommendation	
<b>CMV</b>					
Preemptive strategy recommended over prophylaxis/treatment	Ganciclovir, valganciclovir, or foscarnet	A	I		[177, 239–242]
Reduce incidence of CMV infection/disease, if a center does not follow a preemptive strategy	Long term acyclovir 800 mg/day	C	II		[180]
	Valacyclovir 500 mg qid/day	B	I		[182]
	Ganciclovir 2.5–5 mg/kg bid/day	C	II	Caution: myelotoxicity	[243, 244]
	Valganciclovir 900 mg bid	A	II	Caution: myelotoxicity	[177]
	CMV-specific CTLs	C	II	Not available at every site (considered experimental)	[245]
<b>HBV</b>					
Prevent disease in HBsAG seropositive recipients	Lamivudine 100 mg/day	A	II	Monitor HBV DNA closely, duration until anti-HBs is detected (and HBV-DNA is negative)	[210, 246, 247]
	Entecavir 0.5–1.0 mg/day	A	II		[248–250]
	Tenofovir 245 mg/day	C	III		[251, 252]
Prevent disease in HBsAG seropositive recipients with HBsAG seronegative donors	Additionally vaccinate donor	B	III	Requires long term planning	[253]
Prevent reactivation in recipients who are anti-HBcAG seropositive, DNA viral load: positive	Lamivudine 100 mg/day	B	III		[209]
Prevent reactivation and disease in recipients who are anti-HBcAG seropositive, DNA viral load: negative	Lamivudine 100 mg/day	C	III		
	HBV-DNA/HBsAG monitoring	B	III		[254]

The current standard to improve morbidity and lower mortality is the early initiation of a preemptive therapy against CMV (**AII**) [174]. Duration of screening is usually defined by the time period of the application of immunosuppressive agents or GVHD.

Anti-CMV prophylaxis can only be considered as an option. The long-term administration of ganciclovir resulted in a delay of recovery from CMV-specific T cell immunity [175].

Valganciclovir is so far not officially approved in allo-HCT patients but has been applied in randomized trials [176, 177]. In a randomized controlled trial, valganciclovir prophylaxis was not superior in reducing the incidence of CMV disease or death when compared with PCR-guided preemptive therapy. Delay in virus-specific T cell reconstitution was not observed in patients receiving prophylaxis [177]. Administration of human immune

globulins for prophylaxis or therapy of CMV disease is generally not recommended (**DII**) [178, 179]. Some investigators published efficacy of high-dose acyclovir or its prodrug valacyclovir in the prevention of CMV disease [180–183]. However, acyclovir failed to prevent CMV disease in autologous transplantation and therefore, is not recommended for prophylaxis (**DIII**) [184].

Newer antiviral agents have been evaluated mainly in phase II trials. Maribavir, an oral antiviral agent was studied for prophylaxis. Maribavir inhibits the UL97 viral protein-kinase of human CMV. Despite promising results in a phase II study, a phase III study could not confirm a benefit [185–187]. Another antiviral agent named CMX001 is an orally bioavailable lipid acyclic nucleoside phosphonate and is converted intracellularly to cidofovir diphosphate. Brincidofovir (CMX001) is active in vitro against CMV, including ganciclovir-resistant strains and was assessed in a phase II trial with promising results in prophylaxis [188]. Letermovir (previously known as AIC246) is another anti-CMV agent with a novel mechanism of action targeting the viral terminase subunit pUL56, a component of the terminase complex. This agent demonstrated dose-dependent prophylactic efficacy in a phase II trial [189]. If the ongoing phase III trials confirm these results, a paradigm shift may occur in the future.

New DNA-based vaccination strategies against CMV are being evaluated in clinical trials [190].

Main antiviral recommendations are noted in Table 3.

### Epstein-Barr virus disease prevention

Factors associated with an enhanced risk for Epstein-Barr virus (EBV) replication and therefore infection after allo-HCT are a selective T cell depletion of the graft, a HLA-mismatched transplantation, the choice of an unrelated donor (especially haplo-identical transplant recipients), and the use of T cell depleting antibodies, e.g. alemtuzumab or ATG during conditioning [191, 192]. Early EBV-disease after transplantation is extremely rare. Primary or secondary prophylactic use of antiviral agents is not effective against EBV and therefore not recommended (**DII**) [193, 194]. Close EBV viral load monitoring and rituximab application can be considered as a preemptive therapeutic approach for the prevention of EBV-associated PTLTD after allo-HCT in special high-risk patients (**CIII**) [195–197]. Still considered experimental is the application of cytotoxic T cells for

the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients [198, 199].

### Toxoplasmosis prophylaxis

Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, administered to most transplant patients to prevent *Pneumocystis jirovecii* pneumonia, is also efficacious in preventing toxoplasmosis disease [200, 201].

Clinical reactivation of toxoplasmosis may occur in the late phase after transplantation in seropositive patients under immunosuppression. However, the risk is considerably low and no primary prophylaxis is recommended (**DIII**) [47, 202, 203]. After a successful therapy of toxoplasmosis, secondary prophylaxis should be administered for at least 3 months (**AII<sub>t</sub>**) [204–206] (Table 4).

### Hepatitis A prevention

The incidence of infections due to hepatitis A varies widely. Prevention of hepatitis A by vaccination of seronegative patients or donors follows general vaccination recommendations. A previous exposure to hepatitis A has no impact on transplant-related complications, thus only serologic testing is recommended. In case of IgM seropositivity of the donor and/or recipient, allo-HCT might be postponed since a high risk of transmission or hepatic complications are associated with acute hepatitis A. Additional prevention of infection of the recipient can be achieved by avoiding potentially contaminated food. If exposed, passive immunization has been discussed controversially even in non-transplant patients.

Following patients' post allo-HCT, a continuous loss of acquired hepatitis A antibodies has been described over a median time of 48 months, especially in those older than 18 years. Thus, hepatitis A vaccination should be recommended later in adult transplanted patients at risk (**BII<sub>t</sub>**) [207].

### Hepatitis B prevention (Table 3)

Hepatitis B infection or reactivation contributes to liver-related morbidity and mortality. This is a frequent problem, which occurs in 21–53 % of patients with immunosuppression [208],

**Table 4** Secondary prophylaxis after toxoplasmosis disease

Intention	Intervention	SoR	QoE	Comments	Ref
To prevent relapse of CNS toxoplasmosis	Pyrimethamine (25 mg/day) <sup>a</sup> + sulfadiazine (orally, 30 mg/kg/d)	A	II <sub>t</sub>	Minimum duration for 3 months, many cases longer	[204, 206]
	Pyrimethamine (25 mg/d) <sup>a</sup> + clindamycin (intravenously, 1200 mg/d)	B	II <sub>t</sub>		[255–257]
	Atovaquone 750 mg qid	B	II <sub>t</sub>	In patients intolerant to conventional toxoplasmic encephalitis therapies	[206]

<sup>a</sup> Should be combined with folinic acid



especially after conditioning regimens containing alemtuzumab [209]. The goal is to avoid impairment of liver function, fulminant liver failure, hepatic sinusoidal obstruction syndrome (SOS), cirrhosis, or even hepatocellular cancer [210].

Preferably, HBsAG-negative donors should be selected. However, if no other HLA-compatible donor is available, a positive donor for transplantation is not absolutely contraindicated (**BIII**). Although transplantation of HBV-negative patient with stem cells from an infected donor (HBsAG positive) is associated with a high risk of transmission, some patients develop chronic hepatitis B [210]. Donors with active HBV (DNA detection) should receive antiviral treatment, if possible (**AIII**).

All HBsAG-positive patients awaiting chemotherapy or immunosuppressive therapy should receive antiviral prophylaxis with a nucleoside analogue, regardless of HBV-DNA levels. In anti-HBc positive patients with no detectable viral replication (resolved HBV infection), there is a serious risk (up to 50 %) of reverse seroconversion after allo-HCT [211]. These patients should be monitored for HBV replication on a regular basis and receive preemptive antiviral treatment with lamivudine (**AII**) or entecavir (**AII**) once HBV DNA levels are positive (more details: Table 3). It is recommended that antiviral treatment should be continued until at least 6 months after the cessation of immunosuppression (**BIII**) [29]. Prophylactic treatment of anti-HBc-positive patients without any viral load during the first months after allo-HCT is optional since no data are published in this patient population (**CIII**).

### Hepatitis C prevention

Patients tested positive for HCV-RNA have a significantly higher risk of developing sinusoidal obstruction syndrome (SOS). Long after allo-HCT they suffer a higher rate of liver fibrosis or cirrhosis [34]. Therefore, patients tested positive for HCV-RNA should be considered (if time permitted) to receive highly active antiviral treatment (**BII<sub>t</sub>**) [212]. In allo-HCT, data is lacking; however, Mahale et al. reported that patients who have successfully eliminated HCV are not at risk of reactivation at least after conventional chemotherapy [212]. Detailed therapy recommendations cannot be provided since at this time many promising trials with new drugs are being published demonstrating eradication of HCV [213].

Allo-HCT from an HCV-RNA-positive donor should be avoided since the incidence of transmission remains high (**DII**). If timing permitted and no alternative donor options are available, the donor should be treated accordingly to prevent hepatic complications (**AII<sub>t</sub>**) [214].

### Prevention of diseases caused by respiratory viruses

In recent years, an increasing number of reports on respiratory viral infections after allo-HCT are noted, which are in part attributable to improved diagnostic tools and better awareness.

RSV followed by influenza, parainfluenza, metapneumovirus, and adenovirus are the main viruses causing severe diseases [215]. These viruses can contribute significantly to morbidity after allo-HCT; however, mortality rates seem to be mixed due to heterogeneity of various risk situations [216]. The main recommendation is to avoid infections with these viruses through adequate exposure prevention (**AIII**) [217, 218]. Visitors and staff with signs and symptoms of respiratory infections must avoid visiting the wards to prevent further disease (**AIII**). Additionally, annual influenza vaccination is strongly recommended for healthcare workers, all persons living with allo-HCT candidates or patients to prevent transmission (**AIII**) [219]. If vaccination was carried out during an influenza outbreak, a 2-week course of antiviral chemoprophylaxis could follow until immune response is effective (**BIII**) [19, 220].

There is no published data confirming clinical efficacy of prophylactic administration of respiratory syncytial virus (RSV) immune globulin (RSVIG); therefore, this approach is discouraged (**DII**) [221].

### Intravenous immune globulin for prophylaxis

There is an ongoing controversy about the benefit, dosing, and optimum preparation (hyperimmune or polyvalent) of intravenous immune globulins (IVIG) in allo-HCT [222]. Older studies have demonstrated prevention of infection, interstitial pneumonia (IP), or GVHD [223, 224]. Large meta-analyses demonstrated no clinical benefit, except for a decrease of IP and an increase of sinusoidal obstruction syndrome (SOS) with high-dose IVIG [225, 226].

In a recent multicenter trial, 200 patients received different doses of IVIG or placebo weekly starting day  $-7$  till day  $+100$ , but no differences were observed in regards to infections, interstitial pneumonia, treatment-related mortality, and overall survival. However, higher doses of immune globulin were again associated with deleterious SOS [227]. Therefore, the routine prophylactic substitution of immune globulin is not recommended if the IgG level is  $>4$  g/L (**DI**) [227, 228].

Nevertheless, a retrospective study reported patients with severe hypogammaglobulinemia (e.g. IgG  $<4$  g/L) were to be at risk for decreased survival [229]. This compares well with the IgG substitution recommendations by the IDSA [220] and the guidelines for patients with the common variable immunodeficiency (CVID) syndrome to substitute low-dose immune globulin if IgG  $<4$  g/l [230]. According to an analysis by the Cochrane group, the use of IVIG may be considered in patients with hypogammaglobulinemia associated with CLL or multiple myeloma and recurrent infections. IVIG can significantly decrease the number of infections [225, 226].

Therefore, immune globulin should be replaced in patients with low serum IgG levels and recurrent infections associated with hypogammaglobulinemia to lower the incidence of infections (**BII<sub>t</sub>**).

**Table 5** Vaccination recommendations for allo-HCT recipients

Intention	Intervention (timing of 1st application after allo-HCT)	after application after allo-HCT			SoR	QoE	Comments	Ref
		after day +100	after 6–12 months	after 24 months				
Vaccine								
Provide immunity	<i>Pneumococcus</i> (combination of conjugate and polysaccharide vaccines)	X			A	II <sub>t</sub>	Post allo-HCT 6 months; 3 applications of 13-valent pneumococcal conjugate vaccine (PCV13, 4 weeks apart). After 1 year post allo-HCT use 23-valent polysaccharide pneumococcal vaccine; no data for non-myeloablative, haplo-identical, or DLI protocol regimens Alone not recommended as a single vaccine since conjugate vaccine provide a better immune response	[258, 269–270, 310]
	<i>Pneumococcus</i> (polysaccharide vaccine) 23-valent (PPV23)		(X)		D	II		
	Influenza	X			A	II	Consider to vaccinate patient after 4 weeks again (BI) if still early after transplantion; Include next of kin and healthcare workers (HCW) to receive vaccination as well (AIII). Consider quadrivalent vaccine (BIII).	[266, 271–276]
	<i>Bordetella pertussis</i> (acellular) <sup>b</sup> Diphtheria and tetanus toxoid <sup>a, b</sup>		X		A	III	Antibody levels do not reflect effective vaccination.	[276–278]
			X		A	II	First diphtheria and tetanus vaccination after 12 months; only data available beyond 12 months; for diphtheria higher dose possibly better (child dosage) but not approved (BIII)	[279–281, 310]
	TBE <sup>a</sup> (Tick-borne encephalitis)		X		B	II <sub>t</sub>	Only in endemic areas	[282]
	Poliovirus <sup>a, b</sup>		X		A	II	Inactivated vaccine only	[281, 283–288]
	<i>Haemophilus influenzae</i> (HI) <sup>a, b</sup>		X		B	II	Incidence of HI type B (vs. non type B) infections after allo-HCT is relatively low.	[269, 288–295, 310]
	Meningococcal conjugate vaccine against serogroups A, C, W135, Y and Meningococcal vaccine for serogroup B		X		B	II <sub>t</sub>	Europe, North America and Canada register high rates of meningococcal disease by serogroup B. Therefore, both vaccines are recommended equally.	[295–297]
	Hepatitis A and B (HAV and HBV) <sup>a, b</sup>		X		B	II <sub>t</sub>	Only in patients at risk for hepatitis. Combination vaccination possible. Patients with a previous history of HBV need to be revaccinated (AII).	[33, 207, 298–300]
	MMR (mumps, measles, and rubella; life attenuated vaccine) <sup>a, b</sup>			X	B	II	Live attenuated vaccine after 24 months post allo-HCT and no GVHD or immunosuppressive therapy. Less than 24 months: DIII.	[301–303]
	VZV (varizella zoster virus, life attenuated vaccine) <sup>a</sup>			X	B	II	Consider occupational risks and household. As MMR but no history of VZV disease and seronegative	[304–307]

<sup>a</sup> Consider antibody measurements<sup>b</sup> Consider combination vaccines

## Granulocyte transfusion for prophylaxis

A small matched pair analysis of nine neutropenic patients at high risk for recurrence of a previous fungal infections after allo-HCT demonstrated that prophylactic administration of granulocyte transfusions could reduce the incidence and shorten the duration of fever as well as the duration of neutropenia compared to the control group [231]. Oza et al. performed a “biological randomization” in 151 stem cell recipients dependent on ABO- and CMV-compatibility of their donor. There was a significant decrease in the number of febrile days and the use of intravenous antibiotics; however, no difference in the length of hospital stay or 100-day survival was noted [232]. So far, prophylactic granulocyte transfusion remains an experimental approach and is considered more a therapeutic option.

## Immunization (Tables 5 and 6)

Protection against vaccine-preventable infections should be a part of the post-transplantation medical care management. Ideally, trials should provide evidence for the protection against diseases. However, a study powered for protective

efficacy is not necessary if a sponsor of a vaccine study can justify the use of immunological data to predict protection against infection [233]. If it is not feasible to perform an efficacy study and there is no immunological correlation of protection, it may sometimes be justifiable to gauge the likely efficacy of a vaccine by comparison of immunological responses with those seen in past studies of similar vaccines with proven protective efficacy (e.g., acellular pertussis vaccines) [233].

In allo-HCT recipients, antibody titers against vaccine-preventable infections decline, leading to an increased risk of developing a disease [259]. For this reason, an early vaccination schedule would be warranted. However, during the first 3 to 6 months after transplantation, a sufficient specific immune system response to vaccination cannot be expected [259]. Depending on different factors such as pre- and post-transplant treatment, age, type of transplantation, or presence of chronic GVHD, recovery of the immune system is delayed [259]. Additionally, limited information about vaccine response exists for patients after reduced-intensity conditioning or with umbilical cord blood grafts. Administration of rituximab can suppress humoral immune response as long as 6 months after the last dose. Delayed vaccination schedules should be considered in these patients (**BII<sub>t</sub>**) [260–262].

**Table 6** Immunization schedule

Vaccine	SoR/ QoE	Relative to day of allo-HCT				12 months after first vaccination	Refresher	Comments	Ref
		Day +100	Month +6	Month +7	Month +8				
Pneumococcus	AII <sub>t</sub>	X	X	X		X	Unclear	Start with PCV13, after 12 months after first vaccination the 23 valent polysaccharide vaccine should be used	[269–270, 308]
Influenza	AII	X				X	Annually According to local health advisory	<sup>a</sup> Combination vaccine possible	[266, 271–276]
Polio inactivated <sup>a</sup>	AII		X	X	X	X			[283–288, 309]
Pertussis (acellular) <sup>a</sup>	AIII		X	X	X	X			[277, 278, 309]
Diphtheria and tetanus toxoid <sup>a</sup>	AII		X	X	X	X			[279–282, 292, 309]
<i>Haemophilus influenzae</i> <sup>a</sup>	BII		X	X	X	X			[269, 284, 288–295, 311, 312]
Meningococcal conjugate 4 valent and serogroup B	BII		X			X	None		[295, 313–315]
TBE	BII <sub>t</sub>		X	X		X	5 years		[282, 316]
Hepatitis B	CII		X			X	Depending on titer	Combination vaccine possible (together with HAV)	[298–299, 317–320]
Mumps, measles, rubella	BII	Live attenuated vaccine after 24 months accordingly to the rule mentioned in Table 5					Unclear, depending on immune response	One dose is recommended	[301–303, 321, 322]
Varicella zoster virus (VZV)	BII	Live attenuated vaccine after 24 months accordingly to the rule mentioned in Table 5							[304–307, 323]

<sup>a</sup> combination vaccination possible

Pneumococcal and meningococcal immunization with the conjugated vaccine seems to provide a more stable immune response than the polysaccharide-based vaccine in immature or altered immune systems, but comparative trials are still missing [263].

MMR (measles, mumps, rubella) and *Varicella* vaccines are live attenuated vaccines that should not be given within the first 2 years after transplantation or during active GVHD (**DIII**). A significant risk of disease and side effects in the immunocompromised patient were observed. However, 24 months after transplantation without evidence of chronic GVHD and immunosuppression, MMR vaccine appears safe to be administered (**BIII**).

Routine VZV-vaccination is currently not indicated in seropositive patients for the prevention of herpes zoster (**DIII**). A newer inactivated VZV vaccine is being developed providing adequate VZV-specific antibody titers in most patients [264]. This new vaccine has the potential to change this recommendation in the future.

Additional immunizations against hepatitis A virus, human papillomavirus, yellow fever, cholera, typhus, rotavirus, or pre-exposure rabies virus vaccination are not routinely indicated in adults. Decision-making should follow the recommendations of general population and country-specific policy. Degree of immune suppression against live attenuated vaccines especially in the allo-HCT population needs special attention.

Little is known whether vaccinations can induce GVHD, since viral infections are known to do so [265]. On the other hand, clinical data demonstrate response to vaccination despite GVHD [266, 267]. A group of European experts published results of a consensus conference on vaccination in GVHD [268]. The conference attendees were more cautious about immune suppression. In patients receiving prednisone  $\geq 0.5$  mg/kg bodyweight per day as part of a combination therapy or a three-agent immunosuppressive treatment is given; vaccination may be postponed until immunosuppression is reduced to a double combination or prednisone  $< 0.5$  mg/kg bodyweight daily in order to achieve a better vaccine response (**BIII**) [268].

Antibody titer testing prior to and after immunization can be recommended for many vaccines. Decision-making based on a titer is not recommended for all vaccinations to document efficacy except for VZV, HAV, or HBV. Basically, titer determination provides some insight on vaccination success and should be considered as optional (**CIII**). Testing for sufficient antibody response after immunization is indicated in hepatitis B one month or later after the third vaccine dose (**BIII**). Revaccination with a second series of hepatitis B vaccine should be considered in non-responders (**CIII**).

In review of the available literature, clearly more studies are needed to provide more information on the safety and efficacy of vaccination schedules in allo-HCT.

## Compliance with ethical standards

**Funding source** DGHO (German Society for Hematology and Medical Oncology)

**Conflict of interest** AJU has received support for travel to meetings from Astellas and Basilea. He is a consultant and on the speakers' bureaus of Astellas, Gilead, MSD, and Pfizer. He has also received support for travel and accommodation from Astellas, Boehringer Ingelheim, Gilead, MSD, and Pfizer for activities unrelated to the current study. His institution has received grants from Astellas, Gilead, MSD, and Pfizer.

MSH: none reported.

HB has received support for travel, accommodation, and research grants from Gilead and was an advisor to Gilead.

WJH received research grants from Merck and Pfizer; serves on the speakers bureaus of Alexion, Astellas, Bristol-Myers Squibb, Chugai Pharma, Gilead, Janssen, MSD/Merck, and Pfizer; and received travel grants from Alexion, Astellas, MSD/Merck, Novartis, and Pfizer.

MK is a consultant and on the speakers' bureaus of MSD, and he is a consultant for Gilead and on the speakers' bureau of Astellas.

WK: none reported.

SM: none reported.

SN has received support for travel and accommodation from Celgene, Novartis, and Pfizer for activities unrelated to the current manuscript.

SN: none reported.

OP has received support for travel to meetings from Gilead, MSD, Jazz, and Neovii. He is a consultant of MSD. He has also received research support from Jazz, Neovii, Sanofi, and Takeda

GS: none with regards to the guideline; consultant and speakers' bureaus for MSD, Pfizer, and Gilead; travel grants from Astellas, Gilead, MSD, Pfizer, and Roche unrelated to this manuscript.

JJV is supported by the German Federal Ministry of Research and Education (BMBF grant 01KI0771) and the German Centre for Infection Research, has received research grants from Astellas, Gilead Sciences, Infectopharm, Pfizer, and Essex/Schering-Plough; and served on the speakers' bureau of Astellas, Merck Sharp Dohme/Merck, Gilead Sciences, Pfizer, and Essex/Schering-Plough.

HE: none reported.

GM: received honorarium from Gilead, Pfizer, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb and Merck-Serono. He was also a consultant to Gilead and T2G. He has received support for travel from Pfizer, Roche, Amgen, and Mundipharma.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

1. Tabbara IA et al (2002) Allogeneic hematopoietic stem cell transplantation: complications and results. *Arch Intern Med* 162(14): 1558–1566
2. Hiemenz JW (2009) Management of infections complicating allogeneic hematopoietic stem cell transplantation. *Semin Hematol* 46(3):289–312
3. Einsele H et al (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party



- (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 82(Suppl 2):S175–S185
4. Ullmann AJ et al (2012) ESCMID\* guideline for the diagnosis and management of *Candida* diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. *Clin Microbiol Infect* 18(Suppl 7):1–8
  5. Cornet M et al (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against *Aspergillus* airborne contamination during hospital renovation. *Infect Control Hosp Epidemiol* 20(7):508–513
  6. Eckmanns T, Ruden H, Gastmeier P (2006) The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. *J Infect Dis* 193(10):1408–1418
  7. Oren I et al (2001) Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. *Am J Hematol* 66(4):257–262
  8. Kruger WH et al (2003) Effective protection of allogeneic stem cell recipients against *Aspergillus* by HEPA air filtration during a period of construction—a prospective survey. *J Hematother Stem Cell Res* 12(3):301–307
  9. Vokurka S et al (2014) The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study. *J Clin Nurs* 23(11–12):1648–1652
  10. Humphreys H (2004) Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? *J Hosp Infect* 56(2):93–100, quiz 163
  11. Hayes-Lattin B, Leis JF, Maziarz RT (2005) Isolation in the allogeneic transplant environment: how protective is it? *Bone Marrow Transplant* 36(5):373–381
  12. McCann S et al (2004) Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. *Bone Marrow Transplant* 33(5):519–529
  13. Harrington RD et al (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. *J Infect Dis* 165(6):987–993
  14. Whimbey E et al (1995) Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. *Bone Marrow Transplant* 16(3):393–399
  15. Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. *J Clin Microbiol* 39(2):801–803
  16. McWilliam Leitch EC et al (2001) Dietary effects on the microbiological safety of food. *Proc Nutr Soc* 60(2):247–255
  17. Boyle NM et al (2014) Bacterial foodborne infections after hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 20(11):1856–1861
  18. Allegranzi B, Pittet D (2009) Role of hand hygiene in healthcare-associated infection prevention. *J Hosp Infect* 73(4):305–315
  19. CEI-7 (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *MMWR Recomm Rep* 49(RR-10):1–125
  20. Daeschlein G et al (2007) Hygienic safety of reusable tap water filters (Germlyser) with an operating time of 4 or 8 weeks in a haematological oncology transplantation unit. *BMC Infect Dis* 7:45
  21. Zhou ZY et al (2014) Removal of waterborne pathogens from liver transplant unit water taps in prevention of healthcare-associated infections: a proposal for a cost-effective, proactive infection control strategy. *Clin Microbiol Infect* 20(4):310–314
  22. Cervia JS et al (2010) Point-of-use water filtration reduces healthcare-associated infections in bone marrow transplant recipients. *Transpl Infect Dis* 12(3):238–241
  23. Kelsey SM, Newland AC (1989) Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation. *Bone Marrow Transplant* 4(5):543–546
  24. Hamadani M et al (2010) How we approach patient evaluation for hematopoietic stem cell transplantation. *Bone Marrow Transplant* 45(8):1259–1268
  25. Schmidt-Hieber M et al (2013) CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. *Blood* 122(19):3359–3364
  26. Stewart JA et al (1995) Herpesvirus infections in persons infected with human immunodeficiency virus. *Clin Infect Dis* 21(Suppl 1):S114–S120
  27. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. *J Clin Oncol* 17(1):394–398
  28. Hammond SP et al (2009) Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 15(9):1049–1059
  29. Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. *Blood* 113(14):3147–3153
  30. Knoll A et al (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant* 33(9):925–929
  31. Mikulska M et al (2014) Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. *Clin Microbiol Infect* 20(10):O694–O701
  32. Pompili M et al (2015) Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. *Ann Hepatol* 14(2):168–174
  33. Takahata M et al. (2014) Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. *Transpl Infect Dis* 16(5):797–801
  34. Peffault de Latour R et al (2008) Allogeneic hematopoietic cell transplant in HCV-infected patients. *J Hepatol* 48(6):1008–1017
  35. de Latour Peffault R (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. *Blood* 103(5):1618–1624
  36. Locasciulli A et al (1989) Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. *Transplantation* 48(1):68–72
  37. Lee JH et al (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. *Ann Hematol* 84(5):321–330
  38. van der Eijk AA et al (2014) Hepatitis E virus infection in hematopoietic stem cell transplant recipients. *Curr Opin Infect Dis* 27(4):309–315
  39. Versluis J et al (2013) Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. *Blood* 122(6):1079–1086
  40. le Coutre P et al (2009) Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. *Gut* 58(5):699–702
  41. Bettinger D et al. (2014) Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease. *Ann Hematol* 94(2):359–360



42. Hutter G, Zaia JA (2011) Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. *Clin Exp Immunol* 163(3): 284–295
43. Hutter G et al (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med* 360(7):692–698
44. Hutter G (2014) More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. *N Engl J Med* 371(25):2437–2438
45. Henrich TJ et al (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. *J Infect Dis* 207(11):1694–1702
46. Au WY, Lie AK, Cheng VC (2005) VDRL screening and haemopoietic stem cell transplantation. *Bone Marrow Transplant* 35(10):1027–1028
47. Martino R et al (2005) Early detection of *Toxoplasma* infection by molecular monitoring of *Toxoplasma gondii* in peripheral blood samples after allogeneic stem cell transplantation. *Clin Infect Dis* 40(1):67–78
48. Fricker-Hidalgo H et al (2009) Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. *Clin Infect Dis* 48(2):e9–e15
49. Lee YM et al (2014) A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. *J Infect* 69(2):165–173
50. Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med* 146(5): 340–354
51. Moon SM et al (2013) Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. *Transpl Infect Dis* 15(1):104–109
52. Biehl LM et al (2014) Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. *Crit Rev Microbiol* 42(1):1–16
53. Liss BJ et al (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. *Infection* 40(6):613–619
54. Zirakzadeh A et al (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* 41(4):385–392
55. Dubberke ER et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? *Bone Marrow Transplant* 38(12):813–819
56. Thouverez M, Talon D, Bertrand X (2004) Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. *Infect Control Hosp Epidemiol* 25(10):838–841
57. Blot S et al (2005) Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. *Infect Control Hosp Epidemiol* 26(6):575–579
58. Frere P et al (2004) Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. *Bone Marrow Transplant* 33(7):745–749
59. Mikulska M (2015) How to manage infections caused by antibiotic resistant gram-negative bacteria - EBMT Educational Meeting from the severe aplastic anaemia and infectious diseases working parties, Naples, Italy, 2014. *Curr Drug Targets*
60. Mikulska M, Del Bono V, Viscoli C (2014) Bacterial infections in hematopoietic stem cell transplantation recipients. *Curr Opin Hematol* 21(6):451–458
61. Hammond SP, Baden LR (2007) Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. *Curr Hematol Malig Rep* 2(2):97–103
62. Bucaneve G et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *N Engl J Med* 353(10):977–987
63. Gafter-Gvili A et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. *Cochrane Database Syst Rev* 1:CD004386
64. Cullen M et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *N Engl J Med* 353(10):988–998
65. Leibovici L et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. *Cancer* 107(8):1743–1751
66. Cruciani M et al (2003) Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. *J Clin Oncol* 21(22):4127–4137
67. Kimura S et al (2014) Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. *J Infect* 69(1):13–25
68. Roy V, Ochs L, Weisdorf D (1997) Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. *Leuk Lymphoma* 26(1–2):1–15
69. Ochs L et al (1995) Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. *Blood* 86(10):3979–3986
70. Kulkarni S et al (2000) Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. *Blood* 95(12):3683–3686
71. Mitsui H et al (2003) Analysis of sepsis in allogeneic bone marrow transplant recipients: a single-center study. *J Infect Chemother* 9(3):238–242
72. Taur Y et al (2014) The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood* 124(7):1174–1182
73. Taur Y et al (2012) Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 55(7):905–914
74. Shono Y et al (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. *Sci Transl Med* 8(339):339ra71
75. De Castro N et al (2005) Occurrence of *Pneumocystis jiroveci* pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. *Bone Marrow Transplant* 36(10):879–883
76. Tuan IZ, Dennison D, Weisdorf DJ (1992) *Pneumocystis carinii* pneumonitis following bone marrow transplantation. *Bone Marrow Transplant* 10(3):267–272
77. Williams KM et al (2016) The incidence, mortality and timing of *Pneumocystis jiroveci* pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. *Bone Marrow Transplant* 51(4): 573–580
78. Schneider MM et al (1999) Discontinuation of prophylaxis for *Pneumocystis carinii* pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. *Lancet* 353(9148): 201–203
79. Hughes WT et al (1987) Successful intermittent chemoprophylaxis for *Pneumocystis carinii* pneumonitis. *N Engl J Med* 316(26): 1627–1632

80. Hughes WT et al (1977) Successful chemoprophylaxis for *Pneumocystis carinii* pneumonitis. *N Engl J Med* 297(26):1419–1426
81. Stein DS et al (1991) Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 35(9):1705–1709
82. Stern A et al (2014) Prophylaxis for *Pneumocystis pneumonia* (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst Rev* 10:CD005590
83. Lyytikäinen O et al (1996) Late onset *Pneumocystis carinii* pneumonia following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 17(6):1057–1059
84. Vasconcelles MJ et al (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. *Biol Blood Marrow Transplant* : J Am Soc Blood Marrow Transplant 6(1):35–43
85. Green H et al (2007) Prophylaxis for *Pneumocystis pneumonia* (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst Rev* 3:CD005590
86. Colby C et al (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as *Pneumocystis carinii* pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 24(8):897–902
87. Link H et al (1993) Pentamidine aerosol for prophylaxis of *Pneumocystis carinii* pneumonia after BMT. *Bone Marrow Transplant* 11(5):403–406
88. Marras TK et al (2002) Aerosolized pentamidine prophylaxis for *Pneumocystis carinii* pneumonia after allogeneic marrow transplantation. *Transpl Infect Dis* 4(2):66–74
89. Chan C et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. *J Infect Dis* 180(2):369–376
90. Souza JP et al (1999) High rates of *Pneumocystis carinii* pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. *Clin Infect Dis* 29(6):1467–1471
91. Tomonari A et al (2008) No occurrence of *Pneumocystis jirovecii* (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation. *Transpl Infect Dis* 10(5):303–307
92. Hughes W et al (1993) Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat *Pneumocystis carinii* pneumonia in patients with AIDS. *N Engl J Med* 328(21):1521–1527
93. El-Sadr WM et al (1998) Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group*. *N Engl J Med* 339(26):1889–1895
94. Kontoyiannis DP et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis* 50(8):1091–1100
95. Martino R et al (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. *Br J Haematol* 116(2):475–482
96. Balloy V, Chignard M (2009) The innate immune response to *Aspergillus fumigatus*. *Microbes Infect* 11(12):919–927
97. Zhang P et al (2010) Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. *Transpl Infect Dis* 12(4):316–321
98. Garcia-Vidal C et al (2008) Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. *Clin Infect Dis* 47(8):1041–1050
99. Post MJ et al (2007) Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. *Transpl Infect Dis* 9(3):189–195
100. Lewis RE et al (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with hematological malignancies: a 20-year autopsy study. *Mycoses* 56(6):638–645
101. Sinko J et al (2008) Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. *Transpl Infect Dis* 10(2):106–109
102. Chamilos G et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). *Haematologica* 91(7):986–989
103. Cordonnier C et al (2006) Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. *Clin Infect Dis* 42(7):955–963
104. Cordonnier C et al (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. *Haematologica* 95(10):1762–1768
105. Ostrosky-Zeichner L (2004) Prophylaxis and treatment of invasive candidiasis in the intensive care setting. *Eur J Clin Microbiol Infect Dis* 23(10):739–744
106. Paphitou NI, Ostrosky-Zeichner L, Rex JH (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. *Med Mycol* 43(3):235–243
107. Wenzel RP, Gennings C (2005) Bloodstream infections due to *Candida* species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. *Clin Infect Dis* 41(Suppl 6):S389–S393
108. Ruping MJ et al (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. *J Antimicrob Chemother* 65(2):296–302
109. Neofytos D et al (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. *Clin Infect Dis* 48(3):265–273
110. Cornely OA et al (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. *Antimicrob Agents Chemother* 59(4):2078–2085
111. Marty FM et al. (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis*. doi:10.1016/S1473-3099(16)00071-2
112. Maertens JA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet* 387(10020):760–769
113. Mousset S et al (2014) Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 93(1):13–32
114. Wingard JR et al. (2010) Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). *Blood* 116(24):5111–5118

115. Cornely OA et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 356(4):348–359
116. Duarte RF et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. *Antimicrob Agents Chemother* 58(10):5758–5765
117. Cornely OA et al. (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. *J Antimicrob Chemother* 71(6):1747
118. van Burik JA et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. *Clin Infect Dis* 39(10):1407–1416
119. Marr KA et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. *Blood* 103(4):1527–1533
120. Glasmacher A et al (1998) Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. *Leukemia* 12(9):1338–1343
121. Glasmacher A et al (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. *Mycoses* 42(7–8):443–451
122. Goodman JL et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. *N Engl J Med* 326(13):845–851
123. Marr KA et al (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. *Blood* 96(6):2055–2061
124. Slavin MA et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. *J Infect Dis* 171(6):1545–1552
125. Ullmann AJ et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 356(4):335–347
126. Cordonnier C et al (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. *Bone Marrow Transplant* 33(9):943–948
127. de Fabritiis P et al (2007) Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. *Bone Marrow Transplant* 40(3):245–249
128. Gupta S et al (2007) Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis* 9(2):156–160
129. Wingard JR et al (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis* 29(6):1402–1407
130. Bates DW et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. *Clin Infect Dis* 32(5):686–693
131. Ullmann AJ et al (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. *Clin Infect Dis* 43(4):e29–e38
132. Penack O et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. *Ann Oncol* 17(8):1306–1312
133. Behre GF et al (1995) Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. *Ann Hematol* 71(6):287–291
134. Luu Tran H et al. (2014) Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. *J Oncol Pharm Pract* 22(2):228–234
135. Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. *Clin Pharmacol Ther* 89(3):351–352
136. Kawamura K et al (2014) Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. *Int J Infect Dis* 19:26–32
137. Meyers JD, Flournoy N, Thomas ED (1980) Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. *J Infect Dis* 142(3):338–346
138. Saral R et al (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. *N Engl J Med* 305(2):63–67
139. Gluckman E et al (1983) Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. *Lancet* 2(8352):706–708
140. Wade JC et al (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. *Ann Intern Med* 96(3):265–269
141. Wade JC et al (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. *Ann Intern Med* 100(6):823–828
142. Ljungman P et al (1986) Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. *Bone Marrow Transplant* 1(2):185–192
143. Sauerbrei A et al (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. *Antivir Ther* 16(8):1297–1308
144. McLaren C, Sibrack CD, Barry DW (1982) Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates. *Am J Med* 73(1A):376–379
145. Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. *Antimicrob Agents Chemother* 55(2):459–472
146. Mertz GJ et al (1997) Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *Arch Intern Med* 157(3):343–349
147. Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. *J Infect Dis* 186(Suppl 1):S40–S46
148. Garner JS (1996) Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. *Infect Control Hospital Epidemiol* 17(1):53–80
149. Josephson A, Gombert ME (1988) Airborne transmission of nosocomial varicella from localized zoster. *J Infect Dis* 158(1):238–241
150. Koc Y et al (2000) Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. *Biol Blood Marrow Transplant* 6(1):44–49
151. Rumke HC et al (2011) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. *Vaccine* 29(22):3842–3849
152. Han CS et al (1994) Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. *Bone Marrow Transplant* 13(3):277–283
153. Locksley RM et al (1985) Infection with varicella-zoster virus after marrow transplantation. *J Infect Dis* 152(6):1172–1181
154. Weinstock DM, Boeckh M, Sepkowitz KA (2006) Postexposure prophylaxis against varicella zoster virus infection among



- hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant* 12(10):1096–1097
155. Zaia JA et al (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. *J Infect Dis* 147(4):737–743
  156. Boeckh M et al (2006) Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. *Blood* 107(5):1800–1805
  157. Erard V et al (2007) Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. *J Infect Dis* 196(2):266–270
  158. Thomson KJ et al (2005) The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. *Bone Marrow Transplant* 35(11):1065–1069
  159. Kanda Y et al (2001) Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 28(7):689–692
  160. Gilbert C, Bestman-Smith J, Boivin G (2002) Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. *Drug Resist Updat* 5(2):88–114
  161. Kroger N et al (2001) Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. *Br J Haematol* 113(4):1060–1071
  162. Boeckh M, Nichols WG (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. *Blood* 103(6):2003–2008
  163. Thiele T et al (2011) Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). *Transfusion* 51(12):2620–2626
  164. Narvios AB et al (2005) Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. *Bone Marrow Transplant* 36(6):499–501
  165. Kekre N et al (2013) Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? *Biol Blood Marrow Transplant* 19(12):1719–1724
  166. Bowden RA et al (1991) Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. *Blood* 78(1):246–250
  167. Bowden RA et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. *Blood* 86(9):3598–3603
  168. Miller WJ et al (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. *Bone Marrow Transplant* 7(3):227–234
  169. De Witte T et al (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. *Transplantation* 50(6):964–968
  170. Narvios AB, Lichtiger B (2001) Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. *Haematologica* 86(7):749–752
  171. Zaia JA et al (1997) Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. *J Infect Dis* 176(3):782–785
  172. Nagler A et al (1994) Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation. *Med Oncol* 11(3–4):127–132
  173. Schmidt-Hieber M et al (2010) Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. *Int J Hematol* 91(5):877–885
  174. Einsele H et al (1991) Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. *Lancet* 338(8776):1170–1172
  175. Li CR et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. *Blood* 83(7):1971–1979
  176. O'Brien S et al (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. *Blood* 111(4):1816–1819
  177. Boeckh M et al (2015) Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. *Ann Intern Med* 162(1):1–10
  178. Ruutu T et al (1997) No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. the Nordic BMT Group. *Bone Marrow Transplant* 19(3):233–236
  179. Zikos P et al (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIGG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). *Haematologica* 83(2):132–137
  180. Meyers JD et al (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. *N Engl J Med* 318(2):70–75
  181. Winston DJ et al (2003) Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. *Clin Infect Dis* 36(6):749–758
  182. Ljungman P et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. *Blood* 99(8):3050–3056
  183. Vusirikala M et al (2001) Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. *Bone Marrow Transplant* 28(3):265–270
  184. Boeckh M et al (1995) Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. *J Infect Dis* 172(4):939–943
  185. Winston DJ et al (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. *Blood* 111(11):5403–5410
  186. Avery RK et al (2010) Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. *Transplant Infect Dis* 12(6):489–496
  187. Marty FM et al (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. *Lancet Infect Dis* 11(4):284–292
  188. Marty FM et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. *N Engl J Med* 369(13):1227–1236

189. Chemaly RF et al (2014) Letemovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. *N Engl J Med* 370(19):1781–1789
190. Kharfan-Dabaja MA et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 12(4):290–299
191. Curtis RE et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. *Blood* 94(7):2208–2216
192. Bertz H et al (2009) A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of deesclation. *Biol Blood Marrow Transplant* 15(12):1563–1570
193. Oertel SH, Riess H (2002) Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. *Recent Results Cancer Res* 159:89–95
194. Davis CL et al (1995) Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. *Clin Transplant* 9(1):53–59
195. Liu Q et al (2013) Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. *Am J Hematol* 88(7):550–555
196. Meerbach A et al (2008) Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. *J Med Virol* 80(3):441–454
197. Gruhn B et al (2003) Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 31(11):1023–1025
198. Rooney CM et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. *Blood* 92(5):1549–1555
199. Gerdemann U et al (2012) Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. *Mol Ther* 20(8):1622–1632
200. Yan J et al (2013) Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. *Acta Trop* 127(3):236–244
201. Ruskin J, LaRiviere M (1991) Low-dose co-trimoxazole for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus disease. *Lancet* 337(8739):468–471
202. Bretagne S et al (2000) Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. *Transpl Infect Dis* 2(3):127–132
203. Costa JM et al (2001) Quality control for the diagnosis of *Toxoplasma gondii* reactivation in SCT patients using PCR assays. *Bone Marrow Transplant* 28(5):527–528
204. Katlama C et al (1996) Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. *Clin Infect Dis* 22(2):268–275
205. Podzamczar D et al (1995) Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. *Ann Intern Med* 123(3):175–180
206. Katlama C et al (1996) Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expand Access Group AIDS 10(10):1107–1112
207. Garcia Garrido HM et al. (2015) Response to hepatitis A vaccination in immunocompromised travelers. *J Infect Dis* 212(3):378–385
208. Yeo W et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. *J Med Virol* 62(3):299–307
209. Moses SE et al (2006) Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. *J Med Virol* 78(12):1560–1563
210. Locasciulli A et al (2003) Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/ hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. *Bone Marrow Transplant* 31(4):295–300
211. Knoll A et al (2007) Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. *J Viral Hepat* 14(7):478–483
212. Mahale P, Okhuysen PC, Torres HA (2014) Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? *Clin Gastroenterol Hepatol* 12(6):1051–1054, e1
213. Liang TJ, Ghany MG (2014) Therapy of hepatitis C—back to the future. *N Engl J Med* 370(21):2043–2047
214. (2013) A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the Liver April 24–28, 2013 \* Amsterdam, The Netherlands Special Reporting on: \* Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection\* Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients\* Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations\* Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir\* Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C Infection PLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MD Joan Sanford I. Weill Medical College at Cornell University New York, New York. *Gastroenterol Hepatol (N Y)* 9(6 Suppl 3): 1–18
215. Raboni SM et al (2003) Respiratory tract viral infections in bone marrow transplant patients. *Transplantation* 76(1):142–146
216. Roghmann M et al (2003) Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. *Bone Marrow Transplant* 32(11):1085–1088
217. Sullivan KM et al. (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. *Hematol Am Soc Hematol Educ Program* 392–421
218. Lehnert N et al (2013) Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. *Bone Marrow Transplant* 48(12):1548–1553
219. Ariza-Heredia EJ et al (2015) Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members. *Infect Control Hosp Epidemiol* 36(10):1239–1241
220. Dykewicz CA (2001) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. *Biol Blood Marrow Transplant* 7(Suppl):19S–22S



221. Cortez K et al (2002) Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. *J Infect Dis* 186(6):834–838
222. Robinson P et al (2007) Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. *Transfus Med Rev* 21(2 Suppl 1):S3–S8
223. Sullivan KM et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. *N Engl J Med* 323(11):705–712
224. Winston DJ et al (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. *Ann Intern Med* 106(1):12–18
225. Raanani P et al (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. *J Clin Oncol : Off J Am Soc Clin Oncol* 27(5):770–781
226. Raanani P et al (2008) Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. *Cochrane Database Syst Rev* 4:CD006501
227. Cordonnier C et al (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. *Ann Intern Med* 139(1):8–18
228. Schmidt-Hieber M et al (2009) Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. *Bone Marrow Transplant* 44(3):185–192
229. Norlin AC et al (2008) Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. *Bone Marrow Transplant* 41(3):267–273
230. Sneller MC et al (1993) NIH conference. New insights into common variable immunodeficiency. *Ann Intern Med* 118(9):720–730
231. Kerr JP et al (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. *Br J Haematol* 123(1):114–118
232. Oza A et al (2006) Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. *Transfusion* 46(1):14–23
233. EMA (2006) E.M.A., Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/164653/2005
234. Dignani MC et al (2002) Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. *Bone Marrow Transplant* 29(3):263–267
235. Kim DH et al (2008) Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. *Clin Transplant* 22(6):770–779
236. Erard V et al (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. *Blood* 110(8):3071–3077
237. Oshima K, et al. (2010) One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. *Transpl Infect Dis* 12(5):421–427
238. Asano-Mori Y et al (2008) Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Am J Hematol* 83(6):472–476
239. Einsele H et al (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. *Blood* 86(7):2815–2820
240. Reusser P et al (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 99(4):1159–1164
241. Einsele H et al (2006) Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. *Blood* 107(7):3002–3008
242. Ayala E et al (2006) Valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 37(9):851–856
243. Burns LJ et al (2002) Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. *Bone Marrow Transplant* 30(12):945–951
244. Verdonck LF et al (1997) A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. *Clin Infect Dis* 24(5):901–907
245. Micklethwaite K et al (2007) Ex vivo expansion and prophylactic infusion of CMV-pp 65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 13(6):707–714
246. Lau GK et al (2002) Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. *Hepatology* 36(3):702–709
247. Loomba R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 148(7):519–528
248. Chang TT et al (2006) A comparison of entecavir and lamivudine for HBsAg-positive chronic hepatitis B. *N Engl J Med* 354(10):1001–1010
249. Tamori A et al (2014) Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. *J Gastroenterol Hepatol* 29(9):1715–1721
250. Shang J et al (2016) A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. *Bone Marrow Transplant* 51(4):581–586
251. Koskinas JS et al (2014) The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. a real life experience from a tertiary center. *Eur J Intern Med* 25(8):768–771
252. Leong J et al (2014) Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. *Hepatol Res* 44(12):1248–1252
253. Chiba T et al (2003) Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. *Eur J Haematol* 71(3):220–223
254. Matsue K et al (2009) High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. *Eur J Haematol* 83(4):357–364
255. Foppa CU et al (1991) A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. *Eur J Clin Microbiol Infect Dis* 10(3):187–189
256. Katlama C (1991) Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. *Eur J Clin Microbiol Infect Dis* 10(3):189–191
257. Lepout C et al (1989) An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. *J Infect Dis* 160(3):557–558
258. Cordonnier C et al (2009) Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. *Clin Infect Dis* 48(10):1392–1401

259. Seggewiss R, Einsele H (2010) Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. *Blood* 115(19):3861–3868
260. Eisenberg RA et al (2013) Rituximab-treated patients have a poor response to influenza vaccination. *J Clin Immunol* 33(2):388–396
261. Bedognetti D et al (2011) Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. *J Immunol* 186(10):6044–6055
262. Berglund A et al (2014) The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and *Streptococcus pneumoniae* in adult outpatients with ongoing treatment for cancer with and without rituximab. *Acta Oncol* 53(9):1212–1220
263. Juergens C et al. (2014) Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial. *Hum Vaccin Immunother* 10(5)
264. Hata A et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. *N Engl J Med* 347(1):26–34
265. Burrows SR et al (1997) Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. *Eur J Immunol* 27(7):1726–1736
266. Dhedin N et al (2014) Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. *Vaccine* 32(5):585–591
267. Olkinuora H et al (2012) Immunity after (re) vaccination of paediatric patients following haematopoietic stem cell transplantation. *Acta Paediatr* 101(8):e373–e377
268. Hilgendorf I et al (2011) Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. *Vaccine* 29(16):2825–2833
269. Pao M et al (2008) Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). *Biol Blood Marrow Transplant* 14(9):1022–1030
270. Cordonnier C et al (2010) Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. *Vaccine* 28(15):2730–2734
271. Avetisyan G et al (2008) Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. *Transplantation* 86(2):257–263
272. Ljungman P, Avetisyan G (2008) Influenza vaccination in hematopoietic SCT recipients. *Bone Marrow Transplant* 42(10):637–641
273. Engelhard D et al (1993) Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. *Bone Marrow Transplant* 11(1):1–5
274. Gueller S et al (2011) Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 17(10):1546–1550
275. de Lavallade H et al (2011) Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. *Haematologica* 96(2):307–314
276. Inaba H et al (2012) Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. *Br J Haematol* 156(1):109–117
277. Lambert LC (2014) Pertussis vaccine trials in the 1990s. *J Infect Dis* 209(Suppl 1):S4–S9
278. Edwards KM, Berbers GA (2014) Immune responses to pertussis vaccines and disease. *J Infect Dis* 209(Suppl 1):S10–S15
279. Parkkali T et al (1997) A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. *Bone Marrow Transplant* 19(9):933–938
280. Ljungman P et al (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. *J Infect Dis* 162(2):496–500
281. Li Volti S et al (1994) Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. *Bone Marrow Transplant* 14(2):225–227
282. Dengler TJ et al (1999) Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. *Vaccine* 17(7–8):867–874
283. Ljungman P, Duraj V, Magnusius L (1991) Response to immunization against polio after allogeneic marrow transplantation. *Bone Marrow Transplant* 7(2):89–93
284. Parkkali T et al (1996) Loss of protective immunity to polio, diphtheria and *Haemophilus influenzae* type b after allogeneic bone marrow transplantation. *APMIS* 104(5):383–388
285. Engelhard D et al (1991) Immune response to polio vaccination in bone marrow transplant recipients. *Bone Marrow Transplant* 8(4):295–300
286. Parkkali T et al (1997) Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. *Bone Marrow Transplant* 20(8):663–668
287. Ljungman P et al (2004) Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. *Bone Marrow Transplant* 34(12):1067–1069
288. Parkkali T et al (2007) A randomized study on donor immunization with tetanus-diphtheria, *Haemophilus influenzae* type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 39(3):179–188
289. Barra A et al (1992) Immunogenicity of *Haemophilus influenzae* type b conjugate vaccine in allogeneic bone marrow recipients. *J Infect Dis* 166(5):1021–1028
290. Guinan EC et al (1994) Polysaccharide conjugate vaccine responses in bone marrow transplant patients. *Transplantation* 57(5):677–684
291. Parkkali T et al (1996) A comparison of early and late vaccination with *Haemophilus influenzae* type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. *Bone Marrow Transplant* 18(5):961–967
292. Vance E et al (1998) Comparison of multiple immunization schedules for *Haemophilus influenzae* type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. *Bone Marrow Transplant* 22(8):735–741
293. van Wessel K et al (2011) Nontypeable *Haemophilus influenzae* invasive disease in The Netherlands: a retrospective surveillance study 2001–2008. *Clin Infect Dis* 53(1):e1–e7
294. Kalies H et al (2009) Invasive *Haemophilus influenzae* infections in Germany: impact of non-type b serotypes in the post-vaccine era. *BMC Infect Dis* 9:45
295. Patel SR et al (2007) Revaccination with measles, tetanus, poliovirus, *Haemophilus influenzae* type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. *Clin Infect Dis* 44(5):625–634
296. Jacobsson S et al (2008) Characteristics of *Neisseria meningitidis* isolates causing fatal disease. *Scand J Infect Dis* 40(9):734–744
297. Poolman JT et al (1986) Meningococcal serotypes and serogroup B disease in north-west Europe. *Lancet* 2(8506):555–558

298. Onozawa M et al (2008) HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. *Biol Blood Marrow Transplant* 14(11):1226–1230
299. Jaffe D et al (2006) Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. *Blood* 108(7):2470–2475
300. Idilman R et al (2003) Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. *Clin Transplant* 17(5):438–443
301. Ljungman P et al (1989) Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. *J Infect Dis* 159(4):610–615
302. Spoulou V et al (2004) Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. *Bone Marrow Transplant* 33(12):1187–1190
303. King SM et al (1996) Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. *Bone Marrow Transplant* 17(4):633–636
304. Sauerbrei A et al (1997) Varicella vaccination in children after bone marrow transplantation. *Bone Marrow Transplant* 20(5):381–383
305. Issa NC et al (2014) Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. *Biol Blood Marrow Transplant* 20(2):285–287
306. Kussmaul SC et al (2010) Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. *Bone Marrow Transplant* 45(11):1602–1606
307. Aoki T et al (2016) Safety of live attenuated high-titer varicella-zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients. *Biol Blood Marrow Transplant* 22(4):771–775
308. Cordonnier C et al (2015) Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged  $\geq 2$  years: an open-label study. *Clin Infect Dis* 61(3):313–323
309. Begue PC et al (1998) Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents. *Pediatr Infect Dis J* 17(9):804–809
310. Meerveld-Eggink A et al (2009) Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 15(12):1523–1530
311. Townsend K et al. (2014) Evaluation and validation of a serum bactericidal antibody assay for *Haemophilus influenzae* type b and the threshold of protection. *Vaccine* 32(43):5650–5656
312. Pinson JB, Weart CW (1992) New considerations for *Haemophilus influenzae* type b vaccination. *Clin Pharm* 11(4):332–336
313. Centers for Disease, C. and Prevention (2011) Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease—Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 60(30):1018–1019
314. Toneatto D et al (2011) Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. *Hum Vaccin* 7(7):781–791
315. Mahler MB et al (2012) Safety and immunogenicity of the tetra-valent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 18(1):145–149
316. Beran J, Xie F, Zent O (2014) Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety. *Vaccine* 32(34):4275–4280
317. McMahon BJ et al (2009) Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. *J Infect Dis* 200(9):1390–1396
318. Tung J et al (2010) A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. *Am J Kidney Dis* 56(4):713–719
319. Kim HN et al (2009) Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. *Int J STD AIDS* 20(9):595–600
320. Li Volti S et al (1997) Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 19(2):157–160
321. Fahlgren K (1988) Two doses of MMR vaccine—sufficient to eradicate measles, mumps and rubella? *Scand J Soc Med* 16(3):129–135
322. American Academy of Pediatrics Committee on Infectious Diseases (1997) Immunization of adolescents: recommendations of the advisory committee on immunization practices, the american academy of pediatrics, the american academy of family physicians, and the american medical association. *Pediatrics* 99(3):479–488
323. Nader S et al (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. *J Infect Dis* 171(1):13–17